SCHEMBL24037264

SCHEMBL24037264

CCn1cc(C(=O)O)c(=O)c2nc(Cl)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
HPGD P15428 4/20 0.50
ALDH1A1 P00352 3/20 0.50
HSD17B10 Q99714 3/20 0.50
TSHR P16473 3/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 7/20 0.49
MEN1 O00255 1/20 0.49
ABCC4 O15439 1/20 0.49
PKM P14618 1/20 0.49
PTGS1 P23219 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
APEX1 P27695 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HTT P42858 2/20 0.46
HIF1A Q16665 1/20 0.44
CASP1 P29466 1/20 0.40
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21859026 0.85 LMNA (0.56) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL6451258 0.81 KDM4E (0.50) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL24037435 0.80 USP2 (0.54) KDM4EALDH1A1HSD17B10TSHRLMNA
SCHEMBL4172164 0.78 LMNA (0.74) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL24037263 0.78 TSHR (0.40) KDM4EALDH1A1TSHRLMNAMEN1
SCHEMBL21859073 0.76 LMNA (0.43) KDM4EALDH1A1TSHRLMNAMEN1
SCHEMBL24037529 0.74 HTR2C (0.42) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL24037531 0.74 HTR2C (0.42) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL1366635 0.74 KDM4E (0.68) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL11716631 0.73 KDM4E (0.56) KDM4EHPGDALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210355124-A1 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof BIONOMICS LIMITED (AU) 2021-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355124-A1 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof CHRNA7, CHRNA1, CHRNA5 KDM4E 3556/4885HPGD 496/4885ALDH1A1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.